ScheinfeldN. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005;4(4):637-641. doi:10.1517/14740338.4.4.637
2.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
3.
LiCYDaiYXChenYJ, et al. Cancer risks in vitiligo patients: a nationwide population-based study in Taiwan. Int J Environ Res Public Health. 2018;15(9):1847. doi:10.3390/ijerph15091847
4.
BaeJMKimMLeeHH, et al. Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study. J Invest Dermatol. 2018;138(4):768-774. doi:10.1016/j.jid.2017.11.012
5.
BanLZhangJWangLKuhtreiberWBurgerDFaustmanDL. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci U S A. 2008;105(36):13644-13649. doi:10.1073/pnas.0803429105
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
